Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma. - Wikidata - wikimedia - TriplyDB

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

http://www.wikidata.org/entity/Q37646739

about

The PRMT5 arginine methyltransferase: many roles in development, cancer and beyond Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.Histone H2A and H4 N-terminal tails are positioned by the MEP50 WD repeat protein for efficient methylation by the PRMT5 arginine methyltransferase Chemical biology of protein arginine modifications in epigenetic regulation Targeting protein arginine methyltransferase 5 inhibits human hepatocellular carcinoma growth via the downregulation of beta-catenin.Myc and Omomyc functionally associate with the Protein Arginine Methyltransferase 5 (PRMT5) in glioblastoma cells.Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3 PRMT5 Is Upregulated in HTLV-1-Mediated T-Cell Transformation and Selective Inhibition Alters Viral Gene Expression and Infected Cell Survival.The protein arginine methyltransferase 5 promotes malignant phenotype of hepatocellular carcinoma cells and is associated with adverse patient outcomes after curative hepatectomy PRMT5-Selective Inhibitors Suppress Inflammatory T Cell Responses and Experimental Autoimmune Encephalomyelitis.Elevated expression of protein arginine methyltransferase 5 predicts the poor prognosis of breast cancer.Discovery of selective protein arginine methyltransferase 5 inhibitors and biological evaluations.Histone Modifications and Cancer.A TGFβ-PRMT5-MEP50 axis regulates cancer cell invasion through histone H3 and H4 arginine methylation coupled transcriptional activation and repression.Computational prediction of methylation types of covalently modified lysine and arginine residues in proteins.An update on the epigenetics of glioblastomas.Transcriptional activation of PRMT5 by NF-Y is required for cell growth and negatively regulated by the PKC/c-Fos signaling in prostate cancer cells.Late Cornified Envelope Group I, a novel target of p53, regulates PRMT5 activity.Discovery of a Dual PRMT5-PRMT7 Inhibitor.PRMT5-PTEN molecular pathway regulates senescence and self-renewal of primary glioblastoma neurosphere cells.Protein arginine methyltransferase 5 functions as an epigenetic activator of the androgen receptor to promote prostate cancer cell growth.PRMT5 is required for lymphomagenesis triggered by multiple oncogenic drivers PRMT5 determines the sensitivity to chemotherapeutics by governing stemness in breast cancer.Targeting protein arginine methyltransferase 5 in disease.PRMT5 as a druggable target for glioblastoma therapy.A novel splicing isoform of protein arginine methyltransferase 1 (PRMT1) that lacks the dimerization arm and correlates with cellular malignancy.Sulforaphane suppresses PRMT5/MEP50 function in epidermal squamous cell carcinoma leading to reduced tumor formation.The protein arginine methyltransferase PRMT5 regulates Aβ-induced toxicity in human cells and Caenorhabditis elegans models of Alzheimer's disease.Novel Protein Arginine Methyltransferase 8 Isoform Is Essential for Cell Proliferation.Identification of a Novel Protein Arginine Methyltransferase 5 Inhibitor in Non-small Cell Lung Cancer by Structure-Based Virtual Screening.Protein arginine methylation: an emerging regulator of the cell cycle.Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.

P2860

Q28085672-20CAC271-5BC2-48D6-A74D-B56DD0E90D63 Q34989552-2A2B61E6-534B-4FB9-A1F6-6DE05B23FA08 Q35351891-586AE57C-0C70-4875-8673-ABB91C73464E Q35722457-E2E5E232-844C-4A63-8F1C-2F57454DEDDA Q36255362-1D82A226-D193-41DF-B05F-9C7347D17A54 Q36275660-EC56FC5F-3020-4D60-9E22-57BC3E7E02AA Q36356078-60E90883-4F14-4D5B-8C49-FBEBA4BB20BF Q36507263-E84C0434-3740-40B9-9940-21F859222910 Q37588076-E23268AC-B66F-413C-9DFF-63DCAA578868 Q37625481-A9207969-E792-4B8D-8313-52886A11874D Q38708747-D4F34775-622A-49DE-B20B-6DC63D5A5845 Q38742093-EBFF3815-5399-47D5-9E48-0535117C1287 Q38796064-364BC2DD-CCF9-4711-A086-1A8BC15BADB6 Q38857167-3045E066-9C92-4ECE-87B1-1C6C1B81083F Q38860670-B2860BD8-1A08-4FDB-96A0-4D7B77D34E3C Q38944047-9B62890C-B306-49A4-BD62-63C75C38A7F5 Q38950645-5D5F64EF-42DB-45EA-8E74-F34E791D71B5 Q38956592-720B2904-17D8-4F03-A5A1-6E24DF73D7B2 Q39549990-6FABC8C1-D1E7-4A97-BE59-A324F25A649B Q41818544-0A554DF3-B66A-4ADE-934F-CA042F72F397 Q42036127-1124A87F-55AE-432B-A364-759C99D57E11 Q42702906-FADE5CE2-049C-446B-AD12-A9A537709B41 Q47353645-C7697801-BED3-4FAC-9BAE-C34985E9D7CD Q47404539-283F783C-CB4F-4A5E-AFC5-3C22DC749750 Q47437818-07B667A5-FEB0-44A0-B3C0-8A1A01C5488B Q47878493-49F3BE28-9770-4F23-AD03-365B625F955C Q47882971-76C514B4-4244-496C-8EB3-131771098F25 Q48123133-28E6117D-272B-4850-B129-F2D21548506D Q48924093-08157336-19EC-4921-87A2-57DF0E930C0C Q52353697-217396DB-FDD3-4B15-A0A7-35A37A45FF97 Q52724818-0682671E-B80D-4365-8A45-03ACFE6D2E1A Q55512206-F0083B73-67D0-4395-BA9C-2E1E90144DB4

P2860

Genetic validation of the protein arginine methyltransferase PRMT5 as a candidate therapeutic target in glioblastoma.

http://www.wikidata.org/entity/Q37646739

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 22 January 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Genetic validation of the prot ...... peutic target in glioblastoma.

@en

Genetic validation of the prot ...... peutic target in glioblastoma.

@nl

type

label

Genetic validation of the prot ...... peutic target in glioblastoma.

@en

Genetic validation of the prot ...... peutic target in glioblastoma.

@nl

prefLabel

Genetic validation of the prot ...... peutic target in glioblastoma.

@en

Genetic validation of the prot ...... peutic target in glioblastoma.

@nl

P1433

Q37646739-6CB887DD-717C-4401-9B4E-6D07D4857229

P1476

Q37646739-91E0BBAE-59B4-4C55-978C-CDB45F1EB817

P2093

Q37646739-076288BD-F9FD-4B8F-A197-3FC54A4EAB9C

Q37646739-1D23D732-8FBB-4DB1-AD47-E61A2ADE80B0

Q37646739-22945412-D3AA-449D-AB6E-26A1AD4A9701

Q37646739-232D5522-C39A-4968-B3B9-349375B409E2

Q37646739-24B3CC7A-AF6C-468F-B4D6-5E9BBB65A979

Q37646739-275BF01B-C130-4287-B060-6A2E23ECB004

Q37646739-2F7036A1-1338-4D03-8E44-DEC0FA3F2E7B

Q37646739-30C349F6-E1D2-4B48-BBE5-792821EFD492

Q37646739-44138D45-B9AD-4DFB-B196-DA7FB91CD8F1

Q37646739-49AFF1A0-7254-4429-A7B5-1C2548FC634E

P2860

Q37646739-01A99617-84F7-477B-BAF5-B7C37ACCBC01

Q37646739-01EA9383-8206-43D2-ACEB-A235D51C35B2

Q37646739-02A88291-4E51-4FA7-AAFA-403CCDC4DC7A

Q37646739-07E7DB1B-16CD-4861-A860-E801DA5480BF

Q37646739-0F4B4714-ABF3-479E-807F-C0249A2852B4

Q37646739-125DF8E3-8596-45AE-8EE2-37A39748ABE8

Q37646739-169BF19C-547F-4C4D-BC5F-B2D14684F47B

Q37646739-238FB5AE-9671-4195-B420-C7F2A01D79F3

Q37646739-26CABDBF-6340-4E52-B103-65738FE26541

Q37646739-2DEE0542-F164-4F94-BC85-690DE2F91C39

P304

Q37646739-C639F285-FD35-4554-9BA5-CA285905E31B

P31

Q37646739-A8926410-2992-4F46-9F96-960E22E57190

P356

Q37646739-C6C0E0B0-F378-4DCC-BAAA-90C53F82F6C0

P407

Q37646739-FBCA05BA-B144-4F10-B335-219C6CC95EF6

P433

Q37646739-366FB7D6-87BB-4C25-82F1-C655F1110AA4

P478

Q37646739-D7111DA3-FF8B-4B23-BE94-5BDB499E429B

P50

Q37646739-487B4FCB-59E7-439C-A270-96EBF177BA95

Q37646739-6A539734-0EDA-4B3E-A37C-816C21C899C2

Q37646739-C6BA6688-3FB0-41A9-991A-48BCB80B9827

P577

Q37646739-3F8A2469-EB22-40E2-88B5-F7CEA20E89F0

P5875

Q37646739-FD6100EC-B43B-41E7-BDFB-192824BDC0E3

P698

Q37646739-DE1701F9-D4AB-4ACF-9350-261B19B2E6E7

P932

Q37646739-F2524B22-057D-437B-87B1-585E594B6620

P356

0008-5472.CAN-13-0884

P1433

Cancer Research

P1476

Genetic validation of the prot ...... peutic target in glioblastoma.

@en

P2093

Amy Haseley

http://www.w3.org/2001/XMLSchema#string

Arnab Chakravarti

http://www.w3.org/2001/XMLSchema#string

Balveen Kaur

http://www.w3.org/2001/XMLSchema#string

Bo Yu

http://www.w3.org/2001/XMLSchema#string

Chang-Hyuk Kwon

http://www.w3.org/2001/XMLSchema#string

Chenglong Li

http://www.w3.org/2001/XMLSchema#string

E Antonio Chiocca

http://www.w3.org/2001/XMLSchema#string

Erica Hlavin Bell

http://www.w3.org/2001/XMLSchema#string

Fengting Yan

http://www.w3.org/2001/XMLSchema#string

Gerard Nuovo

http://www.w3.org/2001/XMLSchema#string

P2860

Methylation of ribosomal protein S10 by protein-arginine methyltransferase 5 regulates ribosome biogenesis

Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase

Negative regulation of transcription by the type II arginine methyltransferase PRMT5

Human SWI/SNF-associated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes

An integrated genomic analysis of human glioblastoma multiforme

mSin3A/histone deacetylase 2- and PRMT5-containing Brg1 complex is involved in transcriptional repression of the Myc target gene cad

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Arginine methylation regulates the p53 response

Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31

Expression of the genes of methyl-binding domain proteins in human gliomas

P304

1752-1765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-13-0884

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Ludmila Katherine Martin

P577

2014-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259877986

http://www.w3.org/2001/XMLSchema#string

P698

24453002

http://www.w3.org/2001/XMLSchema#string

P932

3959215

http://www.w3.org/2001/XMLSchema#string